Or, why 2016 might look a little different than 2015 for pharmaceutical marketers.
Massachusetts’ attorney general is studying whether the prices of Gilead Sciences Inc’s blockbuster treatments for hepatitis C violate state law, according to a letter the prosecutor sent to the California drugmaker. The letter from Attorney General Maura Healey to Gilead Chief Executive Officer John Martin, dated January 22, asked the biotechnology company to reconsider its […]
U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences’ new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according to a U.S. Senate investigation into pricing of the blockbuster medicines. In the latest salvo against high U.S. prices for important medicines, the 18-month […]
SURESNES, France– Privately-held Servier, a French pharmaceutical company, will slash 610 employees as it faces increased competition and a tougher regulatory environment, Reuters reported Friday. Reuters said the firm, which employs approximately 21,000 worldwide, said it has faced financial losses due to the end of patents, competition from generic drugs, regulated price controls, increased […]